A
Anne-Marie Wills
Researcher at Harvard University
Publications - 63
Citations - 2820
Anne-Marie Wills is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Disease. The author has an hindex of 19, co-authored 50 publications receiving 2231 citations. Previous affiliations of Anne-Marie Wills include Pfizer & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
miRNA malfunction causes spinal motor neuron disease
Sharon Haramati,Elik Chapnik,Yehezkel Sztainberg,Yehezkel Sztainberg,Raya Eilam,Raaya Zwang,Noga Gershoni,Edwina McGlinn,Patrick W. Heiser,Anne-Marie Wills,Itzhak Wirguin,Lee L. Rubin,Hidemi Misawa,Clifford J. Tabin,Robert H. Brown,Alon Chen,Eran Hornstein +16 more
TL;DR: It is shown that microRNA activity is essential for long-term survival of postmitotic spinal motor neurons (SMNs) in vivo, and it is demonstrated that the heavy neurofilament subunit is a target of miR-9, a miRNA that is specifically down-regulated in a genetic model of SMA.
Journal ArticleDOI
Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis
TL;DR: It is found that dyslipidemia is not an independent predictor of survival in ALS, and BMI is an independent prognostic factor for survival after adjusting for markers of disease severity.
Journal ArticleDOI
Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial
Anne-Marie Wills,Jane Hubbard,Eric A. Macklin,Jonathan D. Glass,Rup Tandan,Ericka Simpson,Benjamin Rix Brooks,Deborah F. Gelinas,Hiroshi Mitsumoto,Tahseen Mozaffar,Gregory P. Hanes,Shafeeq Ladha,Terry Heiman-Patterson,Jonathan S. Katz,Jau-Shin Lou,Katy Mahoney,Daniela L. Grasso,Robert Lawson,Hong Yu,Merit Cudkowicz +19 more
TL;DR: In this article, the safety and tolerability of two hypercaloric diets in patients with amyotrophic lateral sclerosis receiving enteral nutrition was evaluated in a double-blind, placebo-controlled, randomised phase 2 clinical trial.
Journal ArticleDOI
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni,Karl Kieburtz,Barbara C. Tilley,Jordan J. Elm,Bernard Ravina,Debra Babcock,Marina E. Emborg,Robert A. Hauser,Cornelia Kamp,John C. Morgan,G. Webster Ross,David Simon,Jacci Bainbridge,Liana Baker,Ivan Bodis-Wollner,James T. Boyd,Franca Cambi,Julie H. Carter,Kelvin L. Chou,Nabila Dahodwala,Richard B. Dewey,Rohit Dhall,John Y. Fang,Buff Farrow,Andrew Feigin,Sofya Glazman,John L. Goudreau,Pauline LeBlanc,Stephen L. Lee,Maureen A. Leehey,Mark F. Lew,Stephanie Lowenhaupt,Sheng Luo,Rajesh Pahwa,Adriana Pérez,Jay S. Schneider,Burton L. Scott,Binit B. Shah,Kathleen M. Shannon,Saloni Sharma,Carlos Singer,Daniel D. Truong,Renee Wagner,Karen Williams,Anne-Marie Wills,Pei Shieen Wong,Pei Shieen Wong,Cindy Zadikoff,Richard M. Zweig +48 more
TL;DR: It is suggested that pioglitazone at the doses studied here is unlikely to modify progression in early Parkinson's disease.
Journal ArticleDOI
Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis
John Landers,Judith Melki,Vincent Meininger,Jonathan D. Glass,Leonard H. van den Berg,Michael A. van Es,Peter C. Sapp,Peter C. Sapp,Paul W.J. van Vught,Diane McKenna-Yasek,Hylke M. Blauw,Ting Jan Cho,Meraida Polak,Lijia Shi,Anne-Marie Wills,Wendy J. Broom,Nicola Ticozzi,Nicola Ticozzi,Vincenzo Silani,Aslihan Ozoguz,Ildefonso Rodriguez-Leyva,Ildefonso Rodriguez-Leyva,Jan H. Veldink,Adrian J. Ivinson,Christiaan G J Saris,Betsy A. Hosler,Alayna Barnes-Nessa,Nicole R. Couture,John H. J. Wokke,Thomas J. Kwiatkowski,Roel A. Ophoff,Roel A. Ophoff,Simon Cronin,Orla Hardiman,Frank P. Diekstra,P. Nigel Leigh,Christopher Shaw,Claire L. Simpson,Valerie K. Hansen,John Powell,Philippe Corcia,François Salachas,Simon Heath,Pilar Galan,Franck Georges,H. Robert Horvitz,Mark Lathrop,Shaun Purcell,Ammar Al-Chalabi,Robert H. Brown,Robert H. Brown +50 more
TL;DR: Findings support the view that genetic factors modify phenotypes in this disease and that cellular motor proteins are determinants of motor neuron viability.